Mereo Biopharma Group PLC - ESG Rating & Company Profile powered by AI
Scroll down to the bottom of the page for potential risks for Mereo Biopharma Group PLC based on industry, location and marketcap. The ESG rating includes 17 United Nations SDGs including: 'No Poverty', 'Reduced Inequalities' and 'Life below Water'. This ESG score for Mereo Biopharma Group PLC represents its transparency towards the UN Sustainable Development Goals.
Mereo Biopharma Group PLC in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.7; made up of an environmental score of 0.0, social score of 0.0 and governance score of 2.0.
0.7
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1894 | Chongqing Zhifei Biological Products Co Ltd | 0.8 | Low |
| 1894 | Valens Company Inc | 0.8 | Low |
| 1898 | Mereo Biopharma Group PLC | 0.7 | Low |
| 1898 | CKD Bio Corp | 0.7 | Low |
| 1898 | Australis Capital Inc | 0.7 | Low |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Mereo Biopharma Group PLC have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose current and historical energy intensity?
Sign up for free to unlockDoes Mereo Biopharma Group PLC report the average age of the workforce?
Sign up for free to unlockDoes Mereo Biopharma Group PLC reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose its ethnicity pay gap?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose cybersecurity risks?
Sign up for free to unlockDoes Mereo Biopharma Group PLC offer flexible work?
Sign up for free to unlockDoes Mereo Biopharma Group PLC have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Mereo Biopharma Group PLC conduct supply chain audits?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Mereo Biopharma Group PLC conduct 360 degree staff reviews?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose the individual responsible for D&I?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose water use targets?
Sign up for free to unlockDoes Mereo Biopharma Group PLC have careers partnerships with academic institutions?
Sign up for free to unlockDid Mereo Biopharma Group PLC have a product recall in the last two years?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose incidents of discrimination?
Sign up for free to unlockDoes Mereo Biopharma Group PLC allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Mereo Biopharma Group PLC issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose parental leave metrics?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose the pay ratio of women to men?
Sign up for free to unlockDoes Mereo Biopharma Group PLC support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Mereo Biopharma Group PLC reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Mereo Biopharma Group PLC involved in embryonic stem cell research?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose its waste policy?
Sign up for free to unlockDoes Mereo Biopharma Group PLC report according to TCFD requirements?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose energy use targets?
Sign up for free to unlockDoes Mereo Biopharma Group PLC disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Mereo Biopharma Group PLC have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Mereo Biopharma Group PLC
These potential risks are based on the size, segment and geographies of the company.
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.